Showing results (111-120 of 140) with videos related to
Sort By:
Pageof 14
Cancer|October 11, 2013
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancerChristine A Ciunci, Rodolfo F Perini, Anjali N Avadhani, et al.The Lancet. Oncology|July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trialLaurence Albiges, Howard Gurney, Vagif Atduev, et al.Japanese Journal of Clinical Oncology|January 16, 2025
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern AsiaHsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, et al.International Journal of Cancer|June 9, 2023
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trialSun Young Rha, Toni K Choueiri, Vsevolod B Matveev, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 StudyMichael B Atkins, F Stephen Hodi, John A Thompson, et al.Leukemia Research|December 21, 2018
Hepatic and cardiac and iron overload detected by T2* magnetic resonance (MRI) in patients with myelodisplastic syndrome: A cross-sectional studyL F Mantovani, F P S Santos, G F Perini, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinomaN Agarwal, J Brugarolas, P Ghatalia, et al.Ophthalmology|June 7, 2024
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 StudyHenry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.The Lancet. Oncology|April 30, 2022
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 studyRobert Motzer, Camillo Porta, Boris Alekseev, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell CarcinomaDavid F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.Pageof 14